Fairview Capital Investment Management LLC cut its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 4.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,526 shares of the medical instruments supplier’s stock after selling 257 shares during the quarter. Fairview Capital Investment Management LLC’s holdings in C.R. Bard were worth $1,747,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in BCR. BlackRock Inc. increased its stake in C.R. Bard by 1,365.7% in the 1st quarter. BlackRock Inc. now owns 7,398,081 shares of the medical instruments supplier’s stock valued at $1,838,719,000 after buying an additional 6,893,346 shares during the last quarter. Farallon Capital Management LLC bought a new position in shares of C.R. Bard during the 2nd quarter worth approximately $463,101,000. Alpine Associates Management Inc. bought a new position in shares of C.R. Bard during the 2nd quarter worth approximately $265,663,000. MARSHALL WACE ASIA Ltd bought a new position in shares of C.R. Bard during the 1st quarter worth approximately $132,062,000. Finally, Marshall Wace North America L.P. bought a new position in shares of C.R. Bard during the 1st quarter worth approximately $132,062,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

BCR has been the subject of several recent analyst reports. BidaskClub lowered C.R. Bard from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a report on Monday, June 12th. Jefferies Group LLC reiterated a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a report on Thursday, September 14th. Finally, BMO Capital Markets reiterated a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $292.00.

C.R. Bard, Inc. (NYSE:BCR) traded up 0.08% during trading on Monday, reaching $320.75. The company had a trading volume of 163,148 shares. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $324.58. The firm has a market capitalization of $23.31 billion, a PE ratio of 42.11 and a beta of 0.59. The firm’s 50 day moving average price is $320.07 and its 200 day moving average price is $299.22.

C.R. Bard (NYSE:BCR) last issued its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The company had revenue of $979.70 million for the quarter, compared to analysts’ expectations of $976.53 million. During the same quarter last year, the company posted $2.54 earnings per share. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. Equities research analysts forecast that C.R. Bard, Inc. will post $11.84 EPS for the current year.

In other news, insider John P. Groetelaars sold 23,687 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the transaction, the insider now directly owns 31,445 shares of the company’s stock, valued at approximately $10,022,464.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.80% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/fairview-capital-investment-management-llc-has-1-75-million-position-in-c-r-bard-inc-bcr/1603450.html.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.